CABOZANTINIB
Manner of administration:Oral
Restriction (Streamlined authority code: 15774)
Indication: Stage IV renal cell carcinoma (RCC)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $9,472.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cabometyx | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17794)
Indication: Stage IV renal cell carcinoma (RCC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $9,472.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cabometyx | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 15454)
Indication: Locally advanced or metastatic differentiated thyroid cancer
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $9,472.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cabometyx | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17791)
Indication: Locally advanced or metastatic differentiated thyroid cancer
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $9,472.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cabometyx | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17611)
Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine
tumour (pNET) or extra-pancreatic neuroendocrine tumour (epNET)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $9,472.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cabometyx | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17636)
Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine
tumour (pNET) or extra-pancreatic neuroendocrine tumour (epNET)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $9,472.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Cabometyx | |||||